Health Technology Assessment

In a new paper led by OHE, an international team of co-authors considers the evidence for supply-side cost-effectiveness thresholds, providing a set of recommendations for policymakers. In this blog post, Chris Sampson provides an overview of the findings and key messages.

As part of OHE’s presence at ISPOR 2022 in Washington DC, we hosted an issue panel tackling the hot topic of health technology assessment (HTA) of gene therapies.

The National Institute for Health and Care Excellence (NICE) recently issued its first guidance for a digital therapeutic. NICE recommends the use of Sleepio for treating insomnia symptoms in primary care. OHE played a vital role in developing the evidence to support the guidance. In this blog post, Chris Sampson shares the story of how we got there, and some lessons from the experience.

OHE’s Chris Sampson is currently Chair of the ISPOR Open Source Models Special Interest Group (SIG). The SIG recently published their first journal article in Value in Health and will be delivering a Forum at this week’s ISPOR conference. In this blog post, Chris provides some background to the work and an invitation to get involved.

The NICE methods review consultation included a proposal to consider health inequalities more explicitly in their Health Technology Assessment process. But there is still a long way to go before NICE finds a way to tackle all the complexity of this concept. In the following sections we provide an overall view of the main challenges

Priority setting in health is an important, and sometimes controversial topic. In practice, many health technology assessment agencies give a higher weighting to treatments with ‘desirable’ characteristics. For example, treatments for severe and/or rare diseases. In this blog, we review changes to NICE’s manual to include a new ‘severity modifier’.

We live in a world facing many interrelated challenges, and the choices we make about allocating public sector resources have never been more consequential. The perspective taken in an economic evaluation determines the costs and outcomes included in that evaluation and therefore shapes resource allocation and access to new treatments. In this blog, we review the (lack of) changes to NICE’s manual to include elements of a ‘societal perspective’.

Carer quality of life impacts can be included in health technology evaluations, however little guidance is provided. NICE considered providing more guidance as part of their recent methods review. Ultimately, a set of ‘minimum evidence requirements’ were produced, but these were not included...

This blog post is the second in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post provides a critical discussion on a particular topic, including the expected implications of the changes (or lack thereof) in the manual; what is still missing; and what further research is needed.

World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research into rare diseases and orphan medicines.


Subscribe to RSS - Health Technology Assessment